| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,002 |
2,820 |
$750K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,348 |
2,217 |
$568K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,539 |
2,454 |
$497K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
784 |
688 |
$106K |
| 36415 |
Collection of venous blood by venipuncture |
730 |
625 |
$103K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
214 |
205 |
$51K |
| 81001 |
|
299 |
266 |
$40K |
| 80053 |
Comprehensive metabolic panel |
256 |
227 |
$33K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
219 |
186 |
$29K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
147 |
76 |
$23K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
81 |
72 |
$15K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
77 |
67 |
$10K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
33 |
29 |
$8K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
33 |
29 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
32 |
27 |
$6K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
32 |
25 |
$6K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
37 |
31 |
$5K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
19 |
16 |
$3K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
18 |
16 |
$3K |
| J3490 |
Unclassified drugs |
14 |
14 |
$233.91 |